

# Animal Testing Ban – What's next?

**Workshop Date:** 1 April 2014

**Venue:** Halls A1-A4, Hamburg Messe, Messeplatz 1, D-20357 Hamburg

**in-cosmetics®**  
Hamburg, 1-3 April 2014



## SESSION 1 - MORNING / 9.00 – 12.30

### 9.00 - 10.45 Session Part 1: Animal Testing - Regulatory Positions & Approach to Testing Alternatives

09.00 - 09.15 Welcome, Introduction of the Agenda for the Day & the Session Speakers

**Steven L. Hanft, CONUSBAT, Germany**

### 09.15 - 09.45 Animal Testing for Cosmetics in a World-Wide Perspective

- Regulatory positions in major global economies
- Perception of the market participants, manufacturers and consumers
- Role of international organizations in the move towards alternatives: OECD, ICCVAM, etc.
- REACH and alternative testing methods

Speaker: **Dr. Annelie Struessmann, CONUSBAT, Germany**

### 09.45 - 10.30 The EU's Animal Testing Ban

- Overview of the EU's ban history
- 3R-approach – limitations for cosmetics
- The Commission's position paper COM(2013)135/11.3.2013 & PIF Documentation Guidance
- The situation in Europe after the final implementation deadline in March 2013
- Method validation vs. regulatory acceptance
- Outlook on test validation timelines

Speaker: **Dr. Patric Amcoff, Cosmetics Europe [CE], Belgium**

### 10.45 - 12.30 Session Part 2: Existing In-Vitro, In-Silico and In-Chemico Alternatives, Pros/Cons - Significance vs. Animal Test End Point

#### 10.45 - 11.30 Implementing Alternatives to Animal Testing

- OECD Test guidelines, including development of In-vitro, in-silico, in-chemico methods
- Techniques and methods for data gap filling - use of eChemPortal and QSAR Toolbox, etc.
- Development of Adverse Outcome Pathways and their regulatory applications
- Tools and Guidance: Status, documentation, access

Speaker: **Dr. Joop de Knecht, Environment Directorate, OECD, Paris/F**

#### 11.30 - 12.00 Existing Alternative for Skin Irritation / Corrosion

- RHE - sources of cells, cultivation, difference to in-vivo cells, testing criteria
- Alternative tests - other advantages: Human cells vs. animal cells, more basic knowledge on pathways
- Experiences, acceptance

Speaker: **Dr. Christian Pellevoisin, SkinEthic Academy, France**

#### 12.00 - 12.30 3D Tissues for Genotoxicity – A Validation Scenario

- Validation Process – who is involved, what are the steps
- Situation in mutagenicity testing – approached value of the new test

Speaker: **Desmond (Des) Cave, BioReliance, UK**

## SESSION 2 - AFTERNOON / 13.30 - 17.30

### 13.30 - 15.00 Session Part 1: Biochemical Target Mechanisms and Alternative Testing Strategies

13.30 - 14.15 **Skin Toxicology: Biochemical Mechanisms and their Reflection in Toxicological Testing**

- Key considerations in skin safety assessment – the uniqueness of skin
- Testing methods - correlation to biochemical mechanisms and limitations
- The unexplained gap - type 1 immediate hypersensitization
- RIPT - an example for existing limitations in testing
- The functional proteomics premise - what can we borrow from pharmaceuticals?
- Summary and future perspectives

Speaker: **Dr. Nava Dayan, Dr. Nava Dayan LLC, USA**

14.15 - 15.00 **Skin Sensitization as Example of a Comprehensive Testing Strategy**

- Applying the OECD Adverse Outcome Pathway for the sensitization endpoint
- The mosaic pieces for sensitization assessment
- Interpretation – comparison to animal testing results

Speaker: **Dr. Reinhard Kreiling, Clariant, Chair EFfCI Toxicology Working Group, Germany**

15.15 - 17.00 **Session Part 2: Consequences of the Animal Testing Ban for New Product Development**

15.15 - 16.00 **Animal Testing Ban / Marketing Ban - Consequences for Cosmetic Ingredients**

- Cosmetics ingredients – data required
- Animal Testing Ban / Marketing Ban (1223/2009)
- Avoiding animal testing
- Challenges for ingredients including innovations

Speaker: **Ellen Pfrommer, BASF, Germany**

16.00 - 16.30 **Summary on Options, Restrictions & Legal Positions towards Alternative Approaches & Introduction to the Panel Discussion**

16.30 - 17.30 **Panel Discussion based on an Assessment Scenario under the Animal Testing Ban for a New Cosmetic Ingredient in Skin Whitening Products**

Panel: **Dr. Patric Amcoff, Dr. Nava Dayan, Dr. Reinhard Kreiling, Ellen Pfrommer, Dr. Theresa Callaghan\***

\* **Callaghan Consulting International, Hamburg, Germany**